Lieberman 2003 (CPZ).

Methods	Allocation: randomised. Blindness: double. Duration: 52 weeks. Setting: not stated.
Participants	Diagnosis: people with schizophrenia (DSM IV). N=160*. Age= 28.6 years. Sex: 77 F, 83 M. Setting: inpatients. History: naive first episode patients.
Interventions	1. Clozapine + BZ placebo: dose mean 292 mg/day, max 400 mg/day. N=80. 2. Chlorpromazine + BZ: dose mean 319 mg/day, max 600 mg/day; 2 mg/bid (BZ). N=80.
Outcomes	Leaving the study early. Unable to use ‐ Remission 52 weeks. Mental state: BPRS, SANS (no usable data). Global state: CGI, GAF (no usable data). Adverse effects: COSTART, SAESS (no usable data). Physiological measurements: ECG, WBC, serum glucose (no usable data).
Notes	164 patients were randomised. Four of them withdrew before the first administration of medication, thus they report as randomised 160 patients.
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	Randomised ‐ no details
Allocation concealment?	Unclear risk	No details
Blinding? All outcomes	Unclear risk	Double blind, untested
Incomplete outcome data addressed? All outcomes	Low risk	Numbers reported but reasons for attrition not described
Free of selective reporting?	Unclear risk	No details
Free of other bias?	High risk	Funded by Novartis Pharmaceuticals